Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award
Globe Newswire (Thu, 12-Mar 8:00 AM ET)
Globe Newswire (Mon, 9-Mar 4:05 PM ET)
Ardelyx to Participate in Upcoming Investor Conferences
Globe Newswire (Wed, 4-Mar 8:00 AM ET)
Ardelyx-LPGA Partnership Aims to Transform Awareness of Digestive Health for Women
Market Chameleon (Tue, 24-Feb 3:18 AM ET)
Globe Newswire (Tue, 24-Feb 8:00 AM ET)
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Globe Newswire (Thu, 19-Feb 4:01 PM ET)
Market Chameleon (Thu, 5-Feb 3:43 AM ET)
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026
Globe Newswire (Thu, 5-Feb 8:00 AM ET)
Ardelyx Receives New Patent for Tenapanor
Globe Newswire (Tue, 3-Feb 8:29 AM ET)
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA
Globe Newswire (Wed, 28-Jan 8:29 AM ET)
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Ardelyx trades on the NASDAQ stock market under the symbol ARDX.
As of March 26, 2026, ARDX stock price climbed to $5.69 with 2,811,781 million shares trading.
ARDX has a beta of 0.95, meaning it tends to be less sensitive to market movements. ARDX has a correlation of 0.06 to the broad based SPY ETF.
ARDX has a market cap of $1.40 billion. This is considered a Small Cap stock.
Last quarter Ardelyx reported $125 million in Revenue and $.00 earnings per share. This beat revenue expectation by $7 million and missed earnings estimates by -$.01.
In the last 3 years, ARDX traded as high as $10.13 and as low as $3.16.
The top ETF exchange traded funds that ARDX belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
ARDX has underperformed the market in the last year with a price return of +9.6% while the SPY ETF gained +13.4%. However, in the short term, ARDX had mixed performance relative to the market. It has outperformed in the last 3 months, returning -5.0% vs -6.3% return in SPY. But in the last 2 weeks, ARDX shares have been beat by the market, returning -5.0% compared to an SPY return of -4.4%.
ARDX support price is $5.44 and resistance is $5.84 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARDX shares will trade within this expected range on the day.